- Home
- SD vs DRUG Comparison
SD vs DRUG Comparison
Compare SD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | DRUG |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Pharmaceuticals and Biotechnology |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.9M | 707.1M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SD | DRUG |
|---|---|---|
| Price | $16.84 | $71.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $124.00 |
| AVG Volume (30 Days) | ★ 326.4K | 82.6K |
| Earning Date | 06-12-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.52 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $8.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.81 | $23.18 |
| 52 Week High | $18.45 | $123.75 |
Technical Indicators
Market Signals| Indicator | SD | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 35.56 |
| Support Level | $16.38 | $49.47 |
| Resistance Level | $18.16 | $91.00 |
| Average True Range (ATR) | 0.71 | 4.55 |
| MACD | -0.17 | -1.24 |
| Stochastic Oscillator | 34.43 | 9.05 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.